Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2023) Oral polio vaccine stockpile modeling: insights from recent experience. Expert Review of Vaccines 22:1, pages 813-825.
Read now
Read now
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2022) Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036. Expert Review of Vaccines 21:11, pages 1667-1674.
Read now
Read now
John Kofi Odoom, Evangeline Obodai, Gifty Boateng, Stanley Diamenu, Keren Attiku, Patrick Avevor, Ewurabena Duker, Bismarck Boahene, Miriam Eshun, Emmanuel Gberbie & Joseph Kwadwo Larbi Opare. (2021) Detection of vaccine-derived poliovirus circulation by environmental surveillance in the absence of clinical cases. Human Vaccines & Immunotherapeutics 17:7, pages 2117-2124.
Read now
Read now
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2021) Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Review of Vaccines 20:4, pages 449-460.
Read now
Read now
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Review of Vaccines 19:7, pages 661-686.
Read now
Read now
Kimberly M. Thompson & Dominika A. Kalkowska. (2019) Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Review of Vaccines 18:7, pages 725-736.
Read now
Read now
Articles from other publishers (30)
Yuta Kanai, Misa Onishi, Yukino Yoshida, Tomohiro Kotaki, Shohei Minami, Ryotaro Nouda, Moeko Yamasaki, Yasutaka Enoki & Takeshi Kobayashi. (2023) Genetic engineering strategy for generating a stable dsRNA virus vector using a virus-like codon-modified transgene. Journal of Virology 97:10.
Crossref
Crossref
Dominika A. Kalkowska, Eric Wiesen, Steven G. F. Wassilak, Cara C. Burns, Mark A. Pallansch, Kamran Badizadegan & Kimberly M. Thompson. (2023) Worst‐case scenarios: Modeling uncontrolled type 2 polio transmission. Risk Analysis.
Crossref
Crossref
Dominika A. Kalkowska, Steven G. F. Wassilak, Eric Wiesen, Cara C. Burns, Mark A. Pallansch, Kamran Badizadegan & Kimberly M. Thompson. (2023) Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Risk Analysis.
Crossref
Crossref
Dominika A. Kalkowska, Steven G.F. Wassilak, Mark A. Pallansch, Cara C. Burns, Eric Wiesen, Elias Durry, Kamran Badizadegan & Kimberly M. Thompson. (2023) Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine 41, pages A142-A152.
Crossref
Crossref
Lara Lorenzetti, Rustam Haydarov, Emily Namey, Anna Lawton, Hayon Nam, Muhamad Ridwan Hasan, Claude Monj, Surangani Abeyesekera, Maria Amina Kabwau & Ross McIntosh. (2023) Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria. Vaccine 41, pages A128-A135.
Crossref
Crossref
Vachagan Harutyunyan, Arshad Quddus, Mark Pallansch, Simona Zipursky, David Woods, Ann Ottosen, John Vertefeuille & Ian Lewis. (2023) Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal. Vaccine 41, pages A70-A78.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Steven G.F. Wassilak, Stephen L. Cochi & Kimberly M. Thompson. (2023) Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine 41, pages A136-A141.
Crossref
Crossref
Dominika A. Kalkowska, Arend Voorman, Mark A. Pallansch, Steven G.F. Wassilak, Stephen L. Cochi, Kamran Badizadegan & Kimberly M. Thompson. (2023) The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine 41, pages A12-A18.
Crossref
Crossref
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2023) Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Frontiers in Public Health 11.
Crossref
Crossref
Dominika A Kalkowska, Steven GF Wassilak, Eric Wiesen, Concepcion F Estivariz, Cara C Burns, Kamran Badizadegan & Kimberly M Thompson. (2023) Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation. Gates Open Research 7, pages 55.
Crossref
Crossref
Concepcion F. Estivariz, Cara C. Burns & Grace R. Macklin. 2023. Plotkin's Vaccines. Plotkin's Vaccines
914
968.e17
.
E. E. Evreinova, L. M. Khantimirova, V. A. Shevtsov, V. A. Merkulov & V. P. Bondarev. (2022) Promising opportunities to improve polio vaccines. Biological Products. Prevention, Diagnosis, Treatment 22:2, pages 142-153.
Crossref
Crossref
Arooj Nasir, Dumitru Baleanu, Ali Raza, Pervez Anwar, Nauman Ahmed, Muhammad Rafiq & Tahir Nawaz Cheema. (2022) Bio-Inspired Modelling of Disease Through Delayed Strategies. Computers, Materials & Continua 73:3, pages 5717-5734.
Crossref
Crossref
Muhammad Naveed, Dumitru Baleanu, Ali Raza, Muhammad Rafiq & Atif Hassan Soori. (2022) Treatment of Polio Delayed Epidemic Model via Computer Simulations. Computers, Materials & Continua 70:2, pages 3415-3431.
Crossref
Crossref
Eugenio Valdano, Justin T. Okano, Vittoria Colizza, Honore K. Mitonga & Sally Blower. (2021) Using mobile phone data to reveal risk flow networks underlying the HIV epidemic in Namibia. Nature Communications 12:1.
Crossref
Crossref
Youssouf Sereme, Sandra Madariaga Zarza, Hacène Medkour, Inestin Amona, Florence Fenollar, Jean Akiana, Soraya Mezouar, Nicolas Orain, Joana Vitte, Bernard Davoust, Didier Raoult & Oleg Mediannikov. (2021) Stool Serology: Development of a Non-Invasive Immunological Method for the Detection of Enterovirus-Specific Antibodies in Congo Gorilla Faeces. Microorganisms 9:4, pages 810.
Crossref
Crossref
Kimberly M. Thompson. (2021) Modeling and Managing Poliovirus Risks: We are Where we are…. Risk Analysis 41:2, pages 223-228.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Amanda Wilkinson, Ananda S. Bandyopadhyay, Jennifer L. Konopka‐Anstadt, Cara C. Burns, M. Steven Oberste, Steven G. F. Wassilak, Kamran Badizadegan & Kimberly M. Thompson. (2020) Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Risk Analysis 41:2, pages 329-348.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Analysis 41:2, pages 349-363.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Stephen L. Cochi, Stephanie D. Kovacs, Steven G. F. Wassilak & Kimberly M. Thompson. (2020) Updated Characterization of Post‐OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Risk Analysis 41:2, pages 320-328.
Crossref
Crossref
Dominika A. Kalkowska, Richard Franka, Jeff Higgins, Stephanie D. Kovacs, Joseph C. Forbi, Steven G. F. Wassilak, Mark A. Pallansch & Kimberly M. Thompson. (2020) Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria. Risk Analysis 41:2, pages 289-302.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Analysis 41:2, pages 229-247.
Crossref
Crossref
Dominika A. Kalkowska & Kimberly M. Thompson. (2020) Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan. Risk Analysis 41:2, pages 266-272.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Steven G. F. Wassilak, Stephen L. Cochi & Kimberly M. Thompson. (2020) Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. Risk Analysis 41:2, pages 248-265.
Crossref
Crossref
E. Javelle & D. Raoult. (2020) Antibiotics against poliovirus carriage: an additional tool in the polio endgame?. Clinical Microbiology and Infection 26:5, pages 542-544.
Crossref
Crossref
Oliver Razum, Devi Sridhar, Albrecht Jahn, Shehla Zaidi, Gorik Ooms & Olaf Müller. (2019) Polio: from eradication to systematic, sustained control. BMJ Global Health 4:4, pages e001633.
Crossref
Crossref
Kimberly M Thompson. (2019) Polio endgame options: will we have the vaccines needed?. The Lancet 394:10193, pages 99-100.
Crossref
Crossref
Pierre Van Damme, Ilse De Coster, Ananda S Bandyopadhyay, Hilde Revets, Kanchanamala Withanage, Philippe De Smedt, Leen Suykens, M Steven Oberste, William C Weldon, Sue Ann Costa-Clemens, Ralf Clemens, John Modlin, Amy J Weiner, Andrew J Macadam, Raul Andino, Olen M Kew, Jennifer L Konopka-Anstadt, Cara C Burns, John Konz, Rahnuma Wahid & Christopher Gast. (2019) The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. The Lancet 394:10193, pages 148-158.
Crossref
Crossref
Radboud J Duintjer Tebbens, Dominika A Kalkowska & Kimberly M Thompson. (2019) Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission. BMJ Open 9:1, pages e023938.
Crossref
Crossref
D. A. Kalkowska, M. A. Pallansch & K. M. Thompson. (2019) Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiology and Infection 147.
Crossref
Crossref